Visit Website →
← Back to blog

Only One FDA-Approved GH Secretagogue: Mechanism, Dosing, COA Checklist

September 13, 2026
Only One FDA-Approved GH Secretagogue: Mechanism, Dosing, COA Checklist

Growth hormone secretagogues split into two pharmacological families: GHRH receptor agonists and ghrelin/GHSR-1a receptor agonists. The first group includes sermorelin, CJC-1295, and tesamorelin; the second covers ipamorelin, GHRP-2, GHRP-6, hexarelin, and the oral non-peptide MK-677 (ibutamoren). Only tesamorelin carries FDA approval in the US, specifically for HIV-associated lipodystrophy; every other compound on this list remains investigational or compounded.

TL;DR:

  • Tesamorelin is the only growth hormone secretagogue with FDA approval, specifically for HIV-associated lipodystrophy; all others are investigational or compounded substances.
  • Short-acting GHRH analogs like sermorelin and non-DAC CJC-1295 require blood sampling within 15-30 minutes of dosing, while MK-677 produces sustained GH elevations over 4-6 hours.
  • GHRP compounds like GHRP-2, GHRP-6, and hexarelin are injectable with short half-lives, and GHRP-6 and hexarelin have pronounced appetite and off-target hormone effects; ipamorelin is more selective with fewer side effects.
  • Researchers must verify the source and quality of peptides via Certificates of Analysis, ensuring compliance with standards like ISO 17025, and follow strict storage and reconstitution protocols.
  • Use of these secretagogues outside approved indications carries metabolic risks, particularly glucose dysregulation and hormone imbalances, necessitating careful monitoring and medical oversight.
USAPeptide
Support Peptide Research With Better Data
Explore molecular profiles, peer-reviewed summaries, and verified Certificates of Analysis for research-grade peptides.
Explore the peptide reference

Table of Contents

GHRH Receptor Agonists: Sermorelin, CJC-1295, and Tesamorelin

GHRH receptor agonists mimic the body's natural growth hormone releasing hormone. They bind GHRH receptors on pituitary somatotrophs and stimulate a physiologic, pulsatile release of growth hormone rather than a flat, continuous surge. That distinction matters for researchers designing sampling protocols, since GH output from this class still respects the somatostatin brake, unlike some ghrelin agonists at high doses.

Sermorelin was the earliest GHRH analog to reach clinical use, marketed decades ago before being discontinued from mainstream commercial production. It is a 29-amino acid fragment representing the biologically active portion of native GHRH. Its half-life runs roughly 10 to 20 minutes, which means it requires frequent or pulsed dosing to sustain any meaningful effect on pituitary output. Researchers still study it as a reference GHRH analog because its pharmacology is well characterized and its regulatory history in the US is unusually well documented compared to newer peptides. It is typically administered subcutaneously, most often before sleep to align with the body's natural nocturnal GH pulse.

CJC-1295 exists in two distinct forms that researchers should never treat as interchangeable. The version without a Drug Affinity Complex (DAC) behaves similarly to a modified GRF (1-29) fragment, with a half-life of roughly 30 minutes. The DAC-conjugated version binds serum albumin, extending its half-life to several days and producing sustained GHRH receptor stimulation rather than a discrete pulse. That sustained exposure is precisely why some researchers avoid CJC-1295 with DAC in pulsatility studies. It flattens the natural rhythm of GH release, which can interfere with feedback loop modeling. A closer look at CJC-1295's clinical pharmacology shows why the DAC and non-DAC forms produce meaningfully different research applications despite sharing a name.

Tesamorelin stands apart from the rest of this list on regulatory grounds. It carries a stabilized GHRH structure resistant to enzymatic degradation, giving it a longer functional half-life than sermorelin while still preserving a pulsatile release pattern. Phase 3 trial data supporting its FDA approval documented measurable reductions in visceral adipose tissue among patients with HIV-associated lipodystrophy, making it the only agent in this entire class with a Food and Drug Administration-approved indication and an official prescribing label. That label provides detailed adverse-event reporting derived from controlled clinical trials.

Modified GRF (1-29) functions as a shorthand for the truncated GHRH fragment used in CJC-1295 without DAC, and researchers sometimes reference it independently in older literature. It shares the short half-life and rapid clearance profile of unmodified GHRH fragments.

Key comparison points across this family:

  • Mechanism: All four compounds bind the GHRH receptor on pituitary somatotrophs, triggering cyclic AMP-mediated GH release.
  • Route: Subcutaneous injection is standard across sermorelin, CJC-1295, and tesamorelin; none exist in an approved oral form.
  • Half-life: Sermorelin and non-DAC CJC-1295 clear within 10 to 30 minutes; CJC-1295 with DAC persists for days; tesamorelin's stabilized structure gives it an intermediate profile documented in its FDA label.
  • Regulatory standing: Tesamorelin alone holds FDA approval; sermorelin has a discontinued-but-documented history; CJC-1295 and modified GRF remain research-only or compounded substances.
  • Primary use: Tesamorelin targets HIV-associated lipodystrophy in approved clinical use; the others appear almost exclusively in research protocols examining GH axis dynamics, body composition, or aging biology.
  • Safety flags: Injection site reactions, joint pain, and mild glucose changes appear across the class, with tesamorelin's label providing the most granular adverse-event frequencies available for any secretagogue.

The CJC-1295 compound profile breaks down dosing logistics and sourcing considerations for researchers comparing the DAC and non-DAC variants side by side.

Ghrelin Receptor Agonists and Non-Peptide GH Mimetics

The second family works through an entirely different receptor. Ghrelin/GHSR-1a agonists bind the growth hormone secretagogue receptor, a G-protein-coupled receptor distinct from the GHRH receptor, and they stimulate GH release through a calcium-signaling pathway that partially bypasses somatostatin inhibition. That mechanistic difference explains why this group tends to produce a more forceful, less physiologic GH pulse than GHRH analogs, and why off-target hormonal effects show up more often here.

Ipamorelin has become the reference compound for selectivity within this class. Structurally, it is a pentapeptide engineered to activate GHSR-1a with minimal spillover onto other receptors tied to cortisol and prolactin release. A PMC review of growth hormone secretagogues documents ipamorelin's comparatively clean off-target profile relative to older GHRPs, and practitioner literature consistently cites it as the preferred choice when minimizing hypothalamic-pituitary-adrenal axis interference is a study priority. Its half-life runs approximately two hours, longer than most short peptide secretagogues but still short enough to require dosing several times daily in most protocols. The ipamorelin research page covers trial data and pharmacology in more depth for researchers building a dosing rationale.

GHRP-2 is a hexapeptide with stronger GH-releasing potency than ipamorelin but a meaningfully less selective receptor profile. It reliably raises cortisol and prolactin alongside GH, and it also stimulates appetite through ghrelin receptor activation in the hypothalamus, an effect researchers sometimes use intentionally in cachexia or appetite-related studies. Its half-life sits in the range of 20 to 30 minutes. The GHRP-2 compound profile outlines monitoring considerations tied to its cortisol and prolactin effects.

GHRP-6 shares GHRP-2's non-selectivity and adds an even more pronounced appetite-stimulating effect, making it a common choice in research examining ghrelin's orexigenic pathway rather than pure GH secretion. Older literature on this compound is extensive precisely because it was one of the first ghrelin mimetics characterized, but that also means its off-target effect profile is the least favorable of the modern GHRP options. Details on typical research use appear on the GHRP-6 profile page.

Hexarelin is the most potent GH secretagogue among the hexapeptides, but potency comes with a tradeoff. It produces the most pronounced cortisol and prolactin elevation in this entire category and shows evidence of receptor desensitization with repeated dosing, meaning its GH-releasing effect can blunt over sustained use. Some research has also explored hexarelin's cardioprotective signaling independent of the GH axis, an area distinct from its secretagogue activity.

MK-677 (ibutamoren) breaks from every other compound on this list by being orally bioavailable and non-peptide in structure. It activates GHSR-1a much like the injectable GHRPs but does so with a half-life of roughly four to six hours, dramatically longer than any injectable ghrelin agonist. That extended exposure produces sustained elevations in GH and IGF-1 rather than discrete pulses, which raises distinct monitoring needs. MK-677 use correlates with increased appetite, mild fluid retention, and measurable increases in fasting glucose, effects that researchers need to track across a dosing period rather than at a single timepoint.

Anamorelin occupies a narrower niche. It is a ghrelin receptor agonist studied specifically in cancer cachexia and anorexia research rather than general GH-axis work, and it has not followed the same research trajectory as the other compounds here. Its relevance to a general secretagogue reference list is mostly historical and mechanistic rather than practical for typical GH-axis protocols.

Comparative summary across this family:

  • Mechanism: All bind GHSR-1a; ipamorelin does so with the highest selectivity, while GHRP-2, GHRP-6, and hexarelin activate broader downstream signaling.
  • Route: GHRP-2, GHRP-6, ipamorelin, and hexarelin require injection; MK-677 is the only orally active agent in the entire secretagogue class.
  • Half-life: Injectable GHRPs clear within 20 to 30 minutes; ipamorelin persists about two hours; MK-677 extends to 4 to 6 hours.
  • Off-target effects: Cortisol and prolactin elevation increase roughly in the order ipamorelin, GHRP-2, GHRP-6, hexarelin, with hexarelin showing the most pronounced effect.
  • Practical use pattern: Ipamorelin dominates modern selectivity-focused protocols; older GHRPs remain relevant where appetite stimulation is the actual research variable.

The ipamorelin compound profile has additional pharmacology detail for researchers weighing it against the older, less selective GHRPs.

How Half-Life Differences Shape Dosing and Sampling Strategy

Half-life is the variable that dictates almost everything else in a secretagogue protocol, from injection frequency to the exact moment a researcher draws blood. Short-acting peptides like sermorelin and the injectable GHRPs clear in 10 to 30 minutes, meaning their GH-releasing effect is a sharp pulse rather than a plateau. Ipamorelin extends that window to roughly two hours, and MK-677's oral pharmacokinetics push it out to four to six hours, producing sustained rather than pulsatile exposure. CJC-1295 with DAC sits at the far end of the spectrum, with albumin binding extending its effect across days.

That spread creates real design implications:

  1. Match sampling to expected peak timing. Short peptides demand sampling aligned tightly to the predicted GH pulse window, often within 15 to 30 minutes of dosing, while MK-677's sustained exposure calls for measuring trough and steady-state levels instead of chasing a peak that may not exist in the same way.
  2. Consider pairing rationale before stacking compounds. Researchers frequently pair a GHRH analog with a GHRP, such as CJC-1295 with ipamorelin, because the two mechanisms act synergistically. The GHRH analog raises the ceiling for GH release while the ghrelin agonist triggers the pulse, producing a larger combined output than either compound alone.
  3. Account for dosing frequency's effect on pulsatility. Repeated short-acting dosing throughout the day can begin to blunt the natural pulsatile rhythm the GH axis depends on, an effect worth controlling for in any protocol measuring downstream IGF-1 response.
  4. Build IGF-1 measurement into the timeline separately from GH sampling. IGF-1 reflects integrated GH exposure over days, not minutes, so it should be tracked on a separate, longer sampling schedule than acute GH pulse measurements.

Pro Tip: When comparing a short-acting GHRP against MK-677 in the same protocol, run two separate sampling schedules rather than one shared timeline. Forcing both compounds into a single sampling window is the most common design error in secretagogue research, and it flattens out real differences in pulsatile versus sustained GH exposure.

Dosing logistics checklist for protocol design: confirm reconstitution stability windows for lyophilized peptides, verify cold-chain storage compliance from receipt through use, document injection or dosing timing relative to meals (particularly for MK-677, where food intake affects absorption), and pre-register the exact GH and IGF-1 sampling intervals before enrollment begins.

Protocol design stages for peptide sampling

US Regulatory Status: What's Approved, Compounded, or Research-Only

That distinction carries real weight for anyone designing a human protocol:

  • Compounded substances carry documented risk. The FDA has specifically flagged certain bulk drug substances used in compounding as presenting significant safety concerns, largely because compounded material bypasses the standardized manufacturing and testing controls that apply to approved drugs.
  • Research-use labeling matters legally, not just semantically. Peptides sold for laboratory research carry no clinical safety data package and are not intended for human administration outside a controlled research or clinical framework.
  • Sourcing documentation should match the compound's regulatory tier. A tesamorelin protocol can reference the FDA label directly; every other compound requires researchers to rely on published pharmacology literature and supplier-provided Certificates of Analysis instead.
  • Prescriber oversight and IRB review remain the baseline for human protocols. Any study involving human administration of a non-approved secretagogue needs documented prescriber oversight and, where applicable, Institutional Review Board approval before enrollment.
  • Sermorelin's regulatory history is instructive. It once held a marketed status before being discontinued commercially, which is why current sermorelin products in the US market fall under research-use or compounded categories despite the compound's long clinical track record. The sermorelin compound profile covers that history in more detail.

Researchers designing protocols with non-approved compounds should treat supplier documentation as a compliance requirement, not a formality. A Certificate of Analysis that confirms identity and purity is the closest available substitute for the regulatory assurance that an FDA approval would otherwise provide.

Safety Profile: Adverse Effects and Monitoring by Compound

Adverse effects across the secretagogue class cluster around a predictable set of physiologic themes: glucose dysregulation, fluid retention, joint discomfort, and appetite changes. The FDA label for tesamorelin documents these effects with the most precision available anywhere in this compound class, since it derives from controlled phase 3 data rather than observational reports.

Glucose and insulin effects appear across nearly every compound in this list, since GH itself is counter-regulatory to insulin. Researchers monitoring any secretagogue protocol should expect measurable shifts in fasting glucose, with MK-677's sustained exposure profile producing the most consistently documented glucose changes among the ghrelin agonists.

Cortisol and prolactin elevation is where compound selection matters most for safety design. Ipamorelin's selective GHSR-1a activation produces the cleanest off-target profile in this class, while GHRP-2, GHRP-6, and especially hexarelin reliably raise both hormones alongside GH. That gradient should inform which compound a researcher selects when cortisol and prolactin interference would confound a study's primary endpoint.

Edema and joint pain show up across GHRH analogs and ghrelin agonists alike, generally tied to sodium retention driven by elevated GH and IGF-1. Tesamorelin's label documents injection site reactions and arthralgia as among the more frequently reported adverse events in its clinical trial population.

Appetite changes run in opposite directions depending on mechanism. GHRP-6 and hexarelin stimulate appetite through hypothalamic ghrelin pathways, sometimes dramatically, while GHRH analogs produce little to no appetite effect on their own.

Clinical guidance consistently urges caution with off-label secretagogue and growth hormone use: reviews point to limited evidence of functional benefit alongside real metabolic risk, particularly around insulin resistance, when these compounds are used outside a documented clinical indication like tesamorelin's.

A reasonable baseline monitoring panel for any secretagogue research protocol includes fasting glucose and HbA1c, IGF-1 levels drawn on a schedule appropriate to the compound's half-life, basic electrolytes to catch early fluid retention signals, and cortisol or prolactin testing when the compound under study has a documented tendency to elevate either hormone.

  • Fasting glucose and HbA1c at baseline and at defined follow-up intervals.
  • IGF-1 measured on a schedule matched to the compound's exposure profile, not a single arbitrary timepoint.
  • Electrolyte panels to catch early edema before it becomes clinically apparent.
  • Cortisol and prolactin testing reserved for compounds with documented elevation risk, such as GHRP-2, GHRP-6, and hexarelin.
  • Ongoing arthralgia and injection site monitoring, documented consistently across the full study period.

Verifying Research-Grade Quality Before You Order

A Certificate of Analysis is only as trustworthy as the lab that issued it, which is why identity confirmation and purity data need independent verification rather than a glance at a PDF.

  1. Confirm identity first. Mass spectrometry data should match the expected molecular weight for the specific compound and salt form being ordered, not a generic reference value.
  2. Check purity against the ≥99% HPLC benchmark. Anything reported below that threshold warrants a direct question to the supplier about the impurity profile.
  3. Verify endotoxin and residual solvent data where applicable. These figures matter more for compounds intended for any in vivo research use.
  4. Match the batch number on the COA to the batch number on the product label. A mismatch, or a COA with no batch reference at all, is a red flag regardless of how polished the document looks.
  5. Confirm accreditation of the testing lab itself. ISO 17025 accreditation indicates the testing laboratory operates under recognized competence standards, which adds a layer of confidence a standalone COA cannot provide on its own.

Pro Tip: Cross-reference the COA's testing date against the product's received date. A COA generated many months before delivery may not reflect the actual stability of the batch sitting in your freezer.

Storage practices affect data integrity as much as sourcing does. Lyophilized peptides generally remain stable at minus 20 degrees Celsius for extended periods, but once reconstituted, most secretagogues have a materially shorter usable window and should be refrigerated and used within the timeframe specified by the supplier's documentation. A lab SOP should specify reconstitution diluent, storage temperature, and maximum time from reconstitution to use for every compound in active study.

Understanding the difference between research-grade and clinical-grade material matters before any protocol design begins, since the testing rigor and intended-use labeling differ substantially between the two categories. Any protocol involving human subjects needs documented prescriber oversight and IRB review before enrollment, regardless of how well-characterized the compound's research literature happens to be.

What This List Doesn't Tell You About Real-World Outcomes

A biomarker change is not a functional outcome, and that gap gets glossed over constantly in secretagogue discussions. Raising GH and IGF-1 is measurable and repeatable across nearly every compound on this list, but translating that into meaningful changes in strength, body composition, or longevity is a different question entirely, and the evidence base for that leap is thin outside tesamorelin's specific approved indication.

Casual off-label use of these compounds, particularly the ghrelin agonists and MK-677, skips past the monitoring infrastructure that clinical trials build in by design. Tesamorelin earned its approval through controlled trials with defined endpoints and adverse-event tracking. Nothing else in this class has that same evidentiary weight behind it, which means researchers extrapolating findings from one compound to another should do so cautiously, not by assumption.

Collaboration between researchers and qualified suppliers matters more than most protocols acknowledge. The glossary of research peptide terminology is a reasonable starting point for teams still building shared vocabulary around GH pulse dynamics, receptor selectivity, and DAC conjugation before designing a study.

— USAPeptide Team

Resources That Help You Apply This List to Real Protocols

Turning a categorized reference list into an actual research protocol takes more than compound names. It takes verified sourcing, dosing math that accounts for reconstitution and molecular weight, and a way to sanity-check a Certificate of Analysis before it lands in your lab notebook.

USAPeptide

USAPeptide.info builds its resource set specifically around that gap. The peptide database covers molecular profiles and mechanism-of-action detail for every compound discussed here, cross-referenced against the same peer-reviewed literature cited throughout this list. The COA grading tool helps you assess whether a supplier's Certificate of Analysis actually holds up against ISO 17025 standards before you commit to a purchase. A dosage calculator is provided to assist with reconstitution and concentration calculations for research solutions.

For qualified researchers ready to source study-grade material, the Peptriva research peptide resource center connects you to high-purity compounds with verified identity and documented Certificates of Analysis, so the sourcing step matches the same rigor as the rest of your protocol design.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

FAQ

What Are Examples of Growth Hormone Secretagogues?

Common examples include GHRH analogs like sermorelin, CJC-1295, and tesamorelin, plus ghrelin/GHSR-1a agonists like ipamorelin, GHRP-2, GHRP-6, hexarelin, and the oral compound MK-677.

Which GH Secretagogue Is Considered Most Effective?

Effectiveness depends on the endpoint being measured: MK-677 and CJC-1295 with DAC produce the largest sustained GH and IGF-1 increases, but tesamorelin has the strongest clinical evidence base since it is the only agent with FDA-approved phase 3 trial data.

What Is a GH Secretagogue, Exactly?

A GH secretagogue is any compound that stimulates the pituitary gland to release growth hormone, acting through either the GHRH receptor or the ghrelin/GHSR-1a receptor rather than supplying growth hormone directly.

Are Growth Hormone Secretagogues Safe to Use?

Safety varies significantly by compound and use case: tesamorelin has documented safety data from controlled trials supporting its approved indication, while most other secretagogues carry limited evidence of functional benefit and known risks like glucose dysregulation, making medical guidance cautious about off-label use.

What's the Difference Between GHRP and GHRH Compounds?

GHRH analogs (sermorelin, CJC-1295, tesamorelin) bind the GHRH receptor and stimulate a physiologic GH pulse, while GHRPs (GHRP-2, GHRP-6, ipamorelin, hexarelin) bind the separate GHSR-1a ghrelin receptor and often produce a stronger pulse with more off-target cortisol and prolactin effects.